September 19, 2005 -- Genta reported positive results for Genasense, a drug that has failed a number of trials, in a Phase III trial against leukemia, recent IPO ViaCell suspended enrollment in a Phase I test of its lead cord stem cell product, GlaxoSmithKline discovered two cases of serious liver problems in patients taking a new AIDS drug, MedImmune completed an FDA application for a new version of its inhaled flu vaccine, Barrier Therapeutics release positive data on its new acne medication, StemCells answered the FDA concerns that have kept its stem cell product on clinical hold, Inverness Medical will buy a diagnostic division from Thermo Electron for $52.5 million, and Athenagen, a privately held startup focusing on angiogenesis, brought in $5.69 million in its first financing round. Biotech took a small hit today, with the Centient Biotech 200™ off by 22 points at 3878, a loss of .57%. More details...
